Dated developments that affect what you pay for semaglutide, newest first. Each item links to the primary source.
NexLife lowers its compounded semaglutide prices
NexLife's semaglutide plan page now lists $109 a month month to month and $105, $99 and $95 a month on 3-, 6- and 12-month plans, down from $139, $132, $125 and $119 on October 15. Its microdose semaglutide tiles moved to the same prices on November 8.
What it means for cash-pay patients: A 12-month plan now totals $1,140 instead of $1,428. NexLife is still not the lowest price we track: 11 of 23 priced programs list less.
Novo Nordisk reports Q3 2026: Wegovy pen sales fall in the U.S. as the pill grows
Novo's Q3 2026 report (SEC Form 6-K, November 4, 2026) shows U.S. Wegovy pen sales down 13% at constant exchange rates and the Wegovy pill adding DKK 4,178 million; combined U.S. Wegovy sales rose 21%. Novo said about 35% of U.S. Wegovy pen prescriptions were self-pay.
What it means for cash-pay patients: NovoCare's self-pay prices did not change: $349 a month for the pen and $149–$299 for the pill when we checked November 9, 2026. Read our analysis.
Ozari Health expands to two compounded GLP-1 plans, with semaglutide from $86 a month
A paid GlobeNewswire release (syndicated on Yahoo Finance) says Ozari, which first offered compounded semaglutide in May 2026, now sells two plans; Ozari One offers compounded semaglutide with B12 at $86 a month, billed $258 every 3 months, in every state except California, with the same price at every dose and no membership.
What it means for cash-pay patients: It is a prepaid quarterly price for an additive formulation of the kind FDA criticized in its Empower letter; we have not read Ozari's own checkout pages.
FDA's "Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" page (current as of October 1, 2026) lists telehealth red flags, a 28-day discard rule for compounded multi-dose GLP-1 vials and a warning against semaglutide salt forms, and counts 990 adverse-event reports for compounded semaglutide as of May 31, 2026.
What it means for cash-pay patients: If you use a compounded vial, note the first-use date and discard it after 28 days.
Rhode Island Medicaid stops covering GLP-1s prescribed only for weight loss
Under the state's FY2027 budget, Rhode Island Medicaid ended coverage of Wegovy, Zepbound, Saxenda and Foundayo prescribed solely for weight loss from October 1, 2026; coverage continues for type 2 diabetes and other approved uses.
What it means for cash-pay patients: Affected members move to self-pay or stop treatment.
Medicare GLP-1 Bridge runs through December 31, 2027
CMS's Bridge page says eligible Part D enrollees pay $50 a month for covered GLP-1s from July 1, 2026 to December 31, 2027. CMS's BALANCE page (modified September 29, 2026) includes an FAQ on "the BALANCE Model not launching in Medicare in 2027".
What it means for cash-pay patients: Medicare.gov lists Foundayo, Wegovy and the Zepbound KwikPen as covered; people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge.
An FDA press announcement says federal prosecutors in Florida charged two Indian nationals with conspiracy and smuggling over counterfeit Ozempic distributed between July 2023 and April 2024. An indictment is an allegation only.
What it means for cash-pay patients: Buy brand semaglutide only through licensed pharmacies or NovoCare.
FDA warns two websites selling "generic" injectable semaglutide
FDA warning letters 737806 (September 23) and 737810 (September 24), posted October 6, 2026, say onlinegenericmedicine.com and cheapmedicineshop.com sell unapproved, misbranded injectable semaglutide ("Semanat", "Semanext").
What it means for cash-pay patients: There is no FDA-approved generic semaglutide in the U.S.
FDA warning letter 738238 (dated September 18, posted September 22, 2026) says Empower's semaglutide/cyanocobalamin and tirzepatide/niacinamide products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and cites insanitary conditions.
What it means for cash-pay patients: NexLife's plan pages do not name Empower; earlier versions of this site wrongly said they did.
Earlier news items on this page (May–July 2026) were removed on November 9, 2026 because several could not be verified and two misattributed products (for example, Foundayo is an Eli Lilly drug). See the corrections log.
Researched ByDr. Parmis · Medical Researcher · Western University of Health Sciences
Medically Reviewed ByDr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: · This page is informational and does not constitute medical advice.